Success Metrics

Clinical Success Rate
93.3%

Based on 14 completed trials

Completion Rate
93%(14/15)
Active Trials
0(0%)
Results Posted
57%(8 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_1
1
6%
Ph phase_3
7
44%
Ph not_applicable
3
19%
Ph phase_4
3
19%

Phase Distribution

1

Early Stage

0

Mid Stage

10

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
1(7.1%)
Phase 3Large-scale testing
7(50.0%)
Phase 4Post-market surveillance
3(21.4%)
N/ANon-phased studies
3(21.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.3%

14 of 15 finished

Non-Completion Rate

6.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Completed(14)
Terminated(1)
Other(1)

Detailed Status

Completed14
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
93.3%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (7.1%)
Phase 37 (50.0%)
Phase 43 (21.4%)
N/A3 (21.4%)

Trials by Status

completed1488%
terminated16%
unknown16%

Recent Activity

Clinical Trials (16)

Showing 16 of 16 trials
NCT02711202Not Applicable

Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation

Completed
NCT02990806Phase 3

A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)

Completed
NCT03707535Phase 3

To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis

Completed
NCT03478111Phase 3

CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis

Completed
NCT02539368

Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease

Completed
NCT02762838Phase 3

Comparative Clinical Trial of Efficacy and Safety of BCD-055 and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis

Completed
NCT01638715Phase 4

A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action

Completed
NCT02096861Phase 3

Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease

Completed
NCT02762812Phase 3

Comparative Clinical Trial to Evaluate Efficacy and Safety of BCD-055 and Remicade® in Patients With Ankylosing Spondylitis

Completed
NCT00948610Not Applicable

Sleep and Immunity in Rheumatoid Arthritis : Remicade Substudy

Completed
NCT00779935Phase 4

Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)

Completed
NCT00705614

Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035)

Completed
NCT02683564Phase 3

BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis: The UNIFORM Study

Unknown
NCT00778869Phase 4

Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED)

Completed
NCT01438151Not Applicable

Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease

Terminated
NCT01844804Phase 1

A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01)

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16